Qiagen (NYSE:QGEN) Shares Sold by Voya Investment Management LLC

Voya Investment Management LLC lowered its stake in shares of Qiagen (NYSE:QGEN - Free Report) by 52.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 161,325 shares of the company's stock after selling 177,517 shares during the quarter. Voya Investment Management LLC owned 0.07% of Qiagen worth $7,185,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brown Brothers Harriman & Co. bought a new position in shares of Qiagen in the fourth quarter worth $37,000. Geneos Wealth Management Inc. grew its position in shares of Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after buying an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Qiagen by 152.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after buying an additional 526 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in Qiagen in the third quarter worth $53,000. Finally, Smartleaf Asset Management LLC lifted its position in Qiagen by 148.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after acquiring an additional 835 shares during the period. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Price Performance

Shares of NYSE:QGEN traded up $0.95 during midday trading on Friday, reaching $43.15. 1,204,867 shares of the company's stock traded hands, compared to its average volume of 1,124,408. The company has a market cap of $9.59 billion, a P/E ratio of 120.15, a PEG ratio of 2.39 and a beta of 0.62. The company has a fifty day simple moving average of $40.28 and a two-hundred day simple moving average of $41.72. The company has a debt-to-equity ratio of 0.38, a quick ratio of 3.09 and a current ratio of 3.61. Qiagen has a 1 year low of $37.63 and a 1 year high of $49.30.

Qiagen (NYSE:QGEN - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a return on equity of 13.92% and a net margin of 4.23%. Equities analysts predict that Qiagen will post 2.26 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on QGEN shares. Baird R W cut shares of Qiagen from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 19th. Robert W. Baird increased their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. Morgan Stanley reiterated an "equal weight" rating and set a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a research report on Monday, January 6th. UBS Group dropped their price objective on Qiagen from $50.00 to $48.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Finally, Redburn Atlantic downgraded Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Qiagen currently has a consensus rating of "Hold" and a consensus price target of $48.42.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.